| . | Control subjects . | BCP-ALL . | Risk groups BCP-ALLa . | ||
|---|---|---|---|---|---|
| SR . | IR . | HR . | |||
| No. | 57 | 47 | 31 (66%) | 13 (28%) | 3 (6%) |
| Age at diagnosis, y | 5.0 (0–16) | 4.0 (1–16) | 3.0 (1–16) | 10.0 (2–16) | 2.0 (2–6) |
| Male:female ratio | 2 | 1.23 | 1.21 | 1.6 | 0.5 |
| WBC (×109/L) | — | 7.9 (0.9–167) | 7.2 (0.9–92.5) | 15.3 (1.1–110) | 19.6 (5.6–167) |
| CMV (IgG positive) | — | 18 (38%) | 10 (32%) | 7 (53%) | 1 (33%) |
| Cytogenetics BCP-ALL | |||||
| SRb | — | 15/47 | 14 | 1 | — |
| IRc | — | 1/47 | — | 1 | — |
| HRd | — | 2/47 | — | — | 2 |
| ETV6/RUNX1 | — | 16/47 | 10 | 6 | |
| Trisomy 21 | — | 2/47 | — | 2 | — |
| Others (including CN) | — | 11/47 | 7 | 3 | 1 |
| . | Control subjects . | BCP-ALL . | Risk groups BCP-ALLa . | ||
|---|---|---|---|---|---|
| SR . | IR . | HR . | |||
| No. | 57 | 47 | 31 (66%) | 13 (28%) | 3 (6%) |
| Age at diagnosis, y | 5.0 (0–16) | 4.0 (1–16) | 3.0 (1–16) | 10.0 (2–16) | 2.0 (2–6) |
| Male:female ratio | 2 | 1.23 | 1.21 | 1.6 | 0.5 |
| WBC (×109/L) | — | 7.9 (0.9–167) | 7.2 (0.9–92.5) | 15.3 (1.1–110) | 19.6 (5.6–167) |
| CMV (IgG positive) | — | 18 (38%) | 10 (32%) | 7 (53%) | 1 (33%) |
| Cytogenetics BCP-ALL | |||||
| SRb | — | 15/47 | 14 | 1 | — |
| IRc | — | 1/47 | — | 1 | — |
| HRd | — | 2/47 | — | — | 2 |
| ETV6/RUNX1 | — | 16/47 | 10 | 6 | |
| Trisomy 21 | — | 2/47 | — | 2 | — |
| Others (including CN) | — | 11/47 | 7 | 3 | 1 |
Abbreviations: ALL = acute lymphoblastic leukemia; BCP-ALL = pre–B cell acute lymphoblastic leukemia; CMV = cytomegalovirus; CN = cytogenetics negative; HR = high risk; Ig = immunoglobulin; IR = intermediate risk; MLL = mixed lineage leukemia ; NOPHO = Nordic Society of Paediatric Haematology and Oncology; SR = standard risk; WBC = white blood cell count.
aDay 29 in NOPHO ALL 2008 treatment protocol.
bCytogenetics: hyperdiploidy.
cCytogenetics: dic(9; 20), t(1; 19), Ic21amp = AML1.
dCytogenetics: MLL (11q23), hypodiploidy.
| . | Control subjects . | BCP-ALL . | Risk groups BCP-ALLa . | ||
|---|---|---|---|---|---|
| SR . | IR . | HR . | |||
| No. | 57 | 47 | 31 (66%) | 13 (28%) | 3 (6%) |
| Age at diagnosis, y | 5.0 (0–16) | 4.0 (1–16) | 3.0 (1–16) | 10.0 (2–16) | 2.0 (2–6) |
| Male:female ratio | 2 | 1.23 | 1.21 | 1.6 | 0.5 |
| WBC (×109/L) | — | 7.9 (0.9–167) | 7.2 (0.9–92.5) | 15.3 (1.1–110) | 19.6 (5.6–167) |
| CMV (IgG positive) | — | 18 (38%) | 10 (32%) | 7 (53%) | 1 (33%) |
| Cytogenetics BCP-ALL | |||||
| SRb | — | 15/47 | 14 | 1 | — |
| IRc | — | 1/47 | — | 1 | — |
| HRd | — | 2/47 | — | — | 2 |
| ETV6/RUNX1 | — | 16/47 | 10 | 6 | |
| Trisomy 21 | — | 2/47 | — | 2 | — |
| Others (including CN) | — | 11/47 | 7 | 3 | 1 |
| . | Control subjects . | BCP-ALL . | Risk groups BCP-ALLa . | ||
|---|---|---|---|---|---|
| SR . | IR . | HR . | |||
| No. | 57 | 47 | 31 (66%) | 13 (28%) | 3 (6%) |
| Age at diagnosis, y | 5.0 (0–16) | 4.0 (1–16) | 3.0 (1–16) | 10.0 (2–16) | 2.0 (2–6) |
| Male:female ratio | 2 | 1.23 | 1.21 | 1.6 | 0.5 |
| WBC (×109/L) | — | 7.9 (0.9–167) | 7.2 (0.9–92.5) | 15.3 (1.1–110) | 19.6 (5.6–167) |
| CMV (IgG positive) | — | 18 (38%) | 10 (32%) | 7 (53%) | 1 (33%) |
| Cytogenetics BCP-ALL | |||||
| SRb | — | 15/47 | 14 | 1 | — |
| IRc | — | 1/47 | — | 1 | — |
| HRd | — | 2/47 | — | — | 2 |
| ETV6/RUNX1 | — | 16/47 | 10 | 6 | |
| Trisomy 21 | — | 2/47 | — | 2 | — |
| Others (including CN) | — | 11/47 | 7 | 3 | 1 |
Abbreviations: ALL = acute lymphoblastic leukemia; BCP-ALL = pre–B cell acute lymphoblastic leukemia; CMV = cytomegalovirus; CN = cytogenetics negative; HR = high risk; Ig = immunoglobulin; IR = intermediate risk; MLL = mixed lineage leukemia ; NOPHO = Nordic Society of Paediatric Haematology and Oncology; SR = standard risk; WBC = white blood cell count.
aDay 29 in NOPHO ALL 2008 treatment protocol.
bCytogenetics: hyperdiploidy.
cCytogenetics: dic(9; 20), t(1; 19), Ic21amp = AML1.
dCytogenetics: MLL (11q23), hypodiploidy.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
